Search Results - "Takeru Wakatsuki"

Neutralization of the induced VEGF-A potentiates the therapeutic effect of an anti-VEGFR2 antibody on gastric cancer in vivo by Mashima, Tetsuo, Wakatsuki, Takeru, Kawata, Naomi, Jang, Myung-Kyu, Nagamori, Akiko, Yoshida, Haruka, Nakamura, Kenichi, Migita, Toshiro, Seimiya, Hiroyuki, Yamaguchi, Kensei

“…The vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) axis is an essential regulator of angiogenesis and important therapeutic target in cancer…”
Get full text

Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer by Wakatsuki, Takeru, Yamamoto, Noriko, Sano, Takeshi, Chin, Keisho, Kawachi, Hiroshi, Takahari, Daisuke, Ogura, Mariko, Ichimura, Takashi, Nakayama, Izuma, Osumi, Hiroki, Matsushima, Tomohiro, Suenaga, Mitsukuni, Shinozaki, Eiji, Hiki, Naoki, Ishikawa, Yuichi, Yamaguchi, Kensei

“…Background There is growing interest in the clinical significance of intratumoral HER2 heterogeneity. Its prognostic and predictive impacts on trastuzumab…”
Get full text

Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival by Ota, Yumiko, Takahari, Daisuke, Suzuki, Takeshi, Osumi, Hiroki, Nakayama, Izuma, Oki, Akira, Wakatsuki, Takeru, Ichimura, Takashi, Ogura, Mariko, Shinozaki, Eiji, Suenaga, Mitsukuni, Chin, Keisho, Yamaguchi, Kensei

“…Purpose In the ATTRACTION-2 trial, nivolumab significantly improved the survival of advanced gastric cancer patients. The pretreatment neutrophil-to-lymphocyte…”
Get full text

Cancer Dormancy: A Model of Early Dissemination and Late Cancer Recurrence by PAEZ, David, LABONTE, Melissa J, BOHANES, Pierre, WU ZHANG, BENHANIM, Leonor, YAN NING, WAKATSUKI, Takeru, LOUPAKIS, Fotios, LENZ, Heinz-Josef

“…Cancer dormancy is a stage in tumor progression in which residual disease remains occult and asymptomatic for a prolonged period of time. Dormant tumor cells…”
Get full text

Managing a gastrointestinal oncology practice in Japan during the COVID-19 pandemic: single institutional experience in The Cancer Institute Hospital of Japanese Foundation for Cancer Research by Takahari, Daisuke, Shinozaki, Eiji, Wakatsuki, Takeru, Ooki, Akira, Ozaka, Masato, Suzuki, Takeshi, Nakayama, Izuma, Osumi, Hiroki, Kamiimabeppu, Daisaku, Sato, Taro, Ogura, Mariko, Suenaga, Mitsukuni, Chin, Keisho, Yamaguchi, Kensei

“…Coronavirus disease 2019 (COVID-19) was declared to be a global pandemic by the World Health Organization on March 11, 2020. On April 7, 2020, a state of…”
Get full text

Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer by Yagi, Shusuke, Wakatsuki, Takeru, Yamamoto, Noriko, Chin, Keisho, Takahari, Daisuke, Ogura, Mariko, Ichimura, Takashi, Nakayama, Izuma, Osumi, Hiroki, Shinozaki, Eiji, Suenaga, Mitsukuni, Fujisaki, Junko, Ishikawa, Yuichi, Yamaguchi, Kensei, Namikawa, Ken, Horiuchi, Yusuke

“…Background We recently reported the clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using surgical specimens; patients with…”
Get full text

Efficacy of aluminum chloride in severe regorafenib-associated hand-foot skin reactions: a single-arm trial by Nishizawa, Aya, Shinozaki, Eiji, Wakatsuki, Takeru, Satoh, Takahiro, Yamazaki, Naoya, Oyamada, Shunsuke, Ariyoshi, Keisuke, Kihara, Kota, Tsuboi, Masahiro, Yamaguchi, Kensei

“…Regorafenib, a multikinase inhibitor, causes a high frequency of hand-foot skin reactions (HFSRs). The present study evaluated the efficacy of topical aluminum…”
Get full text

KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer by Shimozaki, Keitaro, Shinozaki, Eiji, Yamamoto, Noriko, Imamura, Yu, Osumi, Hiroki, Nakayama, Izuma, Wakatsuki, Takeru, Ooki, Akira, Takahari, Daisuke, Ogura, Mariko, Chin, Keisho, Watanabe, Masayuki, Yamaguchi, Kensei

“…Purpose Although RAS and PIK3CA mutations have been associated with resistance to anti-EGFR antibody in colorectal cancer or trastuzumab in breast cancer,…”
Get full text

Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer by Takahari, Daisuke, Chin, Keisho, Ishizuka, Naoki, Takashima, Atsuo, Minashi, Keiko, Kadowaki, Shigenori, Nishina, Tomohiro, Nakajima, Takako Eguchi, Amagai, Kenji, Machida, Nozomu, Goto, Masahiro, Taku, Keisei, Wakatsuki, Takeru, Shoji, Hirokazu, Hironaka, Shuichi, Boku, Narikazu, Yamaguchi, Kensei

“…Background Trastuzumab with cisplatin and fluoropyrimidines improves overall survival (OS) in patients with HER2-positive advanced gastric cancer (AGC). S-1…”
Get full text

Influence of Sex on the Survival of Patients With Esophageal Cancer by Bohanes, Pierre, Yang, Dongyun, Chhibar, Ruchika S, Labonte, Melissa J, Winder, Thomas, Ning, Yan, Gerger, Armin, Benhaim, Léonor, Paez, David, Wakatsuki, Takeru, Loupakis, Fotios, El-Khoueiry, Rita, Zhang, Wu, Lenz, Heinz-Josef

“…The prognostic value of sex for esophageal cancer survival is currently unclear, and growing data suggest that hormonal influences may account for incidence…”
Get full text

Non‐V600E BRAF mutations and EGFR signaling pathway in colorectal cancer by Osumi, Hiroki, Shinozaki, Eiji, Wakatsuki, Takeru, Suenaga, Mitsukuni, Ichimura, Takashi, Ogura, Mariko, Takahari, Daisuke, Ooki, Akira, Suzuki, Takeshi, Ota, Yumiko, Nakayama, Izuma, Chin, Keisho, Miki, Yoshio, Yamaguchi, Kensei

“…The Raf murine sarcoma viral oncogene homolog B (BRAFV600E) mutation (MT) in metastatic colorectal cancer (CRC) is a well‐known prognostic indicator and a…”
Get full text

Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors by Fukuda, Koshiro, Osumi, Hiroki, Yoshino, Koichiro, Nakayama, Izuma, Fukuoka, Shota, Ogura, Mariko, Wakatsuki, Takeru, Ooki, Akira, Takahari, Daisuke, Chin, Keisho, Yamaguchi, Kensei, Shinozaki, Eiji

“…Few studies have focused on the impact of single-organ pulmonary metastases on progression-free survival and overall survival in patients with metastatic…”
Get full text

Perioperative TAS-118 plus oxaliplatin in patients with locally advanced gastric cancer: APOLLO-11 study by Takahari, Daisuke, Katai, Hitoshi, Takashima, Atsuo, Izawa, Naoki, Ishizuka, Naoki, Ohashi, Manabu, Mikami, Shinya, Wakatsuki, Takeru, Nakayama, Izuma, Chin, Keisho, Ida, Satoshi, Kumagai, Koshi, Nunobe, Souya, Iwasa, Satoru, Shoji, Hirokazu, Wada, Takeyuki, Doi, Ayako, Yoshikawa, Takaki, Sano, Takeshi, Boku, Narikazu, Yamaguchi, Kensei

“…Background We investigated the feasibility of perioperative chemotherapy with S-1 and leucovorin (TAS-118) plus oxaliplatin in patients with locally advanced…”
Get full text

Multicentre single-arm phase II trial evaluating the safety and effiCacy of Panitumumab and iRinOtecan in NeoRAS Wild-type mEtaStatic colorectal cancer patientS (C-PROWESS trial): study protocol by Osumi, Hiroki, Ishizuka, Naoki, Takashima, Atsuo, Kumekawa, Yosuke, Nakano, Daisuke, Shiozawa, Manabu, Denda, Tadamichi, Sawada, Ryoichi, Ouchi, Kota, Wakatsuki, Takeru, Narikazu, Boku, Kato, Ken, Yamaguchi, Kensei, Shinozaki, Eiji

“…IntroductionA new concept of ‘NeoRAS wild-type (WT)’, which means conversion of RAS status from RAS mutant to RAS WT after treatment, has been reported…”
Get full text

Phase II trial of biweekly cetuximab and irinotecan as third‐line therapy for pretreated KRAS exon 2 wild‐type colorectal cancer by Osumi, Hiroki, Shinozaki, Eiji, Mashima, Tetsuo, Wakatsuki, Takeru, Suenaga, Mitsukuni, Ichimura, Takashi, Ogura, Mariko, Ota, Yumiko, Nakayama, Izuma, Takahari, Daisuke, Chin, Keisho, Miki, Yoshio, Yamaguchi, Kensei

“…Efficacy and safety of biweekly cetuximab plus irinotecan were evaluated to provide guidance for its use in Japan as third‐line treatment for pretreated…”
Get full text

Effect of DNA methylation status on first-line anti-epidermal growth factor receptor treatment in patients with metastatic colorectal cancer by Osumi, Hiroki, Ouchi, Kota, Shinozaki, Eiji, Takahashi, Shin, Ooki, Akira, Nakayama, Izuma, Wakatsuki, Takeru, Ogura, Mariko, Takahari, Daisuke, Chin, Keisho, Yamaguchi, Kensei, Ishioka, Chikashi

“…Purpose The CpG island methylator phenotype (CIMP), important for carcinogenesis, is a predictor of prognosis and chemotherapy sensitivity in colorectal cancer…”
Get full text

Association Between Regorafenib Dose and Efficacy Against Metastatic Colorectal Cancer in a Real-World Setting by Hatori, Masahiro, Kawakami, Kazuyoshi, Wakatsuki, Takeru, Shinozaki, Eiji, Kobayashi, Kazuo, Aoyama, Takeshi, Nakano, Yasuhiro, Suzuki, Kenichi, Yamaguchi, Kensei, Hama, Toshihiro

“…The association between regorafenib dosage in the treatment of metastatic colorectal cancer (mCRC) and efficacy is currently not well established. It was…”
Get full text

Treatment efficacy of ramucirumab-containing chemotherapy in patients with alpha-fetoprotein producing gastric cancer by Kamiimabeppu, Daisaku, Wakatsuki, Takeru, Takahari, Daisuke, Fukuda, Naoki, Shimozaki, Keitaro, Osumi, Hiroki, Nakayama, Izuma, Ogura, Mariko, Ooki, Akira, Shinozaki, Eiji, Chin, Keisho, Yamaguchi, Kensei

“…Background Alpha-Fetoprotein Producing Gastric Cancer (AFPGC) is an aggressive subgroup of gastric cancer. Recently ramucirumab has shown survival benefits in…”
Get full text

Associations among plasma concentrations of regorafenib and its metabolites, adverse events, and ABCG2 polymorphisms in patients with metastatic colorectal cancers by Kobayashi, Kazuo, Sugiyama, Erika, Shinozaki, Eiji, Wakatsuki, Takeru, Tajima, Masataka, Kidokoro, Hiyori, Aoyama, Takeshi, Nakano, Yasuhiro, Kawakami, Kazuyoshi, Hashimoto, Koki, Suenaga, Mitsukuni, Ichimura, Takashi, Ogura, Mariko, Chin, Keisho, Nakayama, Izuma, Ooki, Akira, Takahari, Daisuke, Suzuki, Wataru, Yokokawa, Takashi, Minowa, Yuichi, Hiraoka, Tomoko, Suzuki, Kenichi, Sato, Hitoshi, Hama, Toshihiro, Yamaguchi, Kensei

“…Purpose The association between the pharmacokinetics and pharmacodynamics of regorafenib, a multiple tyrosine kinase inhibitor, remains unclear. This study…”
Get full text

Endoscopic ultrasound-guided fine-needle aspiration of solid pancreatic masses with rapid on-site cytological evaluation by endosonographers without attendance of cytopathologists by Hikichi, Takuto, Irisawa, Atsushi, Bhutani, Manoop S, Takagi, Tadayuki, Shibukawa, Goro, Yamamoto, Go, Wakatsuki, Takeru, Imamura, Hidemichi, Takahashi, Yuta, Sato, Ai, Sato, Masaki, Ikeda, Tsunehiko, Hashimoto, Yuko, Tasaki, Kazuhiro, Watanabe, Kazuo, Ohira, Hiromasa, Obara, Katsutoshi

“…Background Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) with rapid on-site evaluation (ROSE) has been reported to provide a more accurate…”
Get full text